This study could be used as reference in treating chronic phase CML patients with HU and IM in daily practice and to do follow-up studies evaluating P-gp overexpression as a predictor of treatment outcome. Here, PGP is linked to chronic myelogenous leukemia, BCR-ABL1 positive.